ICRISAT is the latest CGIAR Centre to get into bed with the Beijing Genomics Institute (BGI), following IRRI and CIAT. One does wonder whether if the Centres had approached BGI as a group rather than singly, in the context of the much-vaunted restructuring of the CG system, they might not have extracted a better deal from the shrewd gene-jockeys of Beijing.
LATER: Or is the real news, as a message we have received hints, that some CG Centres have NOT succumbed to the blandishments of BGI, because of worries over intellectual property issues? But again, if that is indeed a problem, would not a joint approach have been able to drive a harder bargain on IPR as well as cost? I don’t know. I’m just asking.